Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Subungual Melanoma of the Hand

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Feasibility of Real-Time Near-Infrared Fluorescence Tracer Imaging in Sentinel Node Biopsy for Oral Cavity Cancer Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Immunterapi ved småcellet lungekræft

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC in Elderly and Frail Patients. A Real-Life Experience.

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

  4. Improving the prognosis for lung cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sven-Petter Haugvik
  • Eva Tiensuu Janson
  • Pia Österlund
  • Seppo W Langer
  • Ragnhild Sørum Falk
  • Knut Jørgen Labori
  • Lene Weber Vestermark
  • Henning Grønbæk
  • Ivar Prydz Gladhaug
  • Halfdan Sorbye
View graph of relations

BACKGROUND: This study aimed to evaluate the role of surgery for patients with high-grade pancreatic neuroendocrine carcinoma (hgPNEC) in a large Nordic multicenter cohort study. Prior studies evaluating the role of surgery for patients with hgPNEC are limited, and the benefit of the surgery is uncertain.

METHODS: Data from patients with a diagnosis of hgPNEC determined between 1998 and 2012 were retrospectively registered at 10 Nordic university hospitals. Kaplan-Meier curves were used to compare the overall survival of different treatment groups, and Cox-regression analysis was used to evaluate factors potentially influencing survival.

RESULTS: The study registered 119 patients. The median survival period from the time of metastasis was 23 months for patients undergoing initial resection of localized nonmetastatic disease and chemotherapy at the time of recurrence (n = 14), 29 months for patients undergoing resection of the primary tumor and resection/radiofrequency ablation of synchronous metastatic liver disease (n = 12), and 13 months for patients with synchronous metastatic disease given systemic chemotherapy alone (n = 78). The 3-year survival rate after surgery of the primary tumor and metastatic disease was 69 %. Resection of the primary tumor was an independent factor for improved survival after occurrence of metastatic disease.

CONCLUSIONS: Patients with resected localized nonmetastatic hgPNEC and later metastatic disease seemed to benefit from initial resection of the primary tumor. Patients selected for resection of the primary tumor and synchronous liver metastases had a high 3-year survival rate. Selected patients with both localized hgPNEC and metastatic hgPNEC should be considered for radical surgical treatment.

Original languageEnglish
JournalAnnals of Surgical Oncology
Volume23
Issue number5
Pages (from-to)1721-8
Number of pages8
ISSN1068-9265
DOIs
Publication statusPublished - May 2016

    Research areas

  • Adult, Aged, Aged, 80 and over, Carcinoma, Neuroendocrine, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Scandinavian and Nordic Countries, Survival Rate, Young Adult, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

ID: 49699016